LakeShore Biopharma's Special Committee retains advisors to review revised proposal.

LakeShore Biopharma has announced that its independent special committee has retained Kroll, LLC as its financial advisor and Gibson, Dunn & Crutcher LLP and Maples and Calder (Hong Kong) LLP as legal counsel. The committee is evaluating a revised preliminary non-binding proposal letter dated August 26, 2025. The Board cautions shareholders that no decisions have been made regarding the proposal.

LakeShore Biopharma (NASDAQ: LSB), a global biopharmaceutical company, has announced significant developments in its evaluation process of a revised preliminary non-binding proposal letter received on August 26, 2025. The company's independent special committee, formed to assess the proposal, has retained Kroll, LLC as its financial advisor, Gibson, Dunn & Crutcher LLP as its U.S. legal counsel, and Maples and Calder (Hong Kong) LLP as its Cayman Islands legal counsel LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee^[1]LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee^[2].

The special committee, under the guidance of these advisors, is continuing its review and evaluation of the proposal. As of the latest update, no definitive decisions have been made regarding the proposal. The company has emphasized that there is no guarantee of a definitive offer, agreement execution, or transaction approval. This cautious approach is intended to ensure a thorough and informed evaluation process LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee^[2].

LakeShore Biopharma, previously known as YS Biopharma, is dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company operates in China, Singapore, and the Philippines and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee^[2].

This announcement comes as part of the company's ongoing efforts to maintain transparency and provide updates to its shareholders. The company has stated that it does not undertake any obligation to provide further updates unless required by applicable law. This approach is consistent with its commitment to adhering to regulatory requirements and ensuring that all stakeholders are well-informed LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee^[2].

The market will closely watch the developments at LakeShore Biopharma as the company navigates this critical evaluation process. Any definitive decisions or updates will likely have significant implications for the company's shareholders and the broader biopharmaceutical industry.

For further information, please visit LakeShore Biopharma's investor relations page: https://investors.lakeshorebio.com/.

Citations:
LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee^[1]: https://www.stocktitan.net/news/LSB/lake-shore-biopharma-announces-appointment-of-independent-financial-v1ppdzy6wc63.html
LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee^[2]: https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-appointment-of-independent-financial-advisor-and-legal-counsel-to-the-special-committee-302552480.html